Achilles Therapeutics plc
ACHLNASDAQHealthcare
$1.48
+$0.01(+0.68%)
Market Cap$60828000
P/E Ratio—
52W High$1.51
52W Low$0.63
Achilles Therapeutics plc (ACHL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACHL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.07B | $0.06B | $0.04B | $0.02B | $0.01B |
| G&A Expenses | $0.02B | $0.02B | $0.02B | $0.01B | $0.00B |
| Total Operating Expenses | $0.08B | $0.08B | $0.06B | $0.03B | $0.01B |
| Operating Income | ($0.08B) | ($0.08B) | ($0.06B) | ($0.03B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.07B) | ($0.06B) | ($0.03B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.07B) | ($0.06B) | ($0.03B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.74 | $-1.82 | $-2.13 | $-0.82 | $-20.50 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.03B | 0.04B | 0.00B |
| EBITDA | ($0.07B) | ($0.07B) | ($0.06B) | ($0.03B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Achilles Therapeutics plc data
About Achilles Therapeutics plc (ACHL) Income Statement
Achilles Therapeutics plc (ACHL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ACHL reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.07B) — a net profit margin of —.
Frequently asked questions
ACHL · 4 questionsAchilles Therapeutics plc (ACHL) reported revenue of $0.00B for 2023, down —% year-over-year.
ACHL revenueACHL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09